

GLAXOSMITHKLINE PLC
Form 6-K
October 12, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 12 October 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Andrew Witty
 - b) Position/status Chief Executive Officer
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | | | | | | | | | | |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----------|--|----------|------------------------|--|----------|---------------------|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | | | | | | | |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's ShareReward Plan. | | | | | | | | | |
| c) Price(s) and volume(s) | <table border="0" style="width: 100%;"> <tr> <td style="width: 15%;">Price(s)</td> <td style="width: 15%;">Volume(s)</td> <td></td> </tr> <tr> <td>£17.2781</td> <td>7 (partnership shares)</td> <td></td> </tr> <tr> <td>£17.2781</td> <td>7 (matching shares)</td> <td></td> </tr> </table> | Price(s) | Volume(s) | | £17.2781 | 7 (partnership shares) | | £17.2781 | 7 (matching shares) | |
| Price(s) | Volume(s) | | | | | | | | | |
| £17.2781 | 7 (partnership shares) | | | | | | | | | |
| £17.2781 | 7 (matching shares) | | | | | | | | | |
| d) Aggregated information | 14 Ordinary Shares | | | | | | | | | |
| Aggregated volume Price | £17.2781 | | | | | | | | | |
| e) Date of the transaction | 2016-10-11 | | | | | | | | | |
| f) Place of the transaction | London Stock Exchange (XLON) | | | | | | | | | |

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | |
|------------------------------------------------------|---------------------------------------------------------------------------------------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's ShareReward Plan. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £17.2781 7 (partnership shares) £17.2781 7 (matching shares) |
| d) Aggregated information Aggregated volume Price | 14 Ordinary Shares £17.2781 |
| e) Date of the transaction | 2016-10-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|---------------------------------------|-------------------------|
| a) Name | Mr S Dingemans |
| b) Position/status | Chief Financial Officer |
| c) Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|------------------------------------------------------|---------------------------------------------------------------------------------------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's ShareReward Plan. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £17.2781 7 (partnership shares) £17.2781 7 (matching shares) |
| d) Aggregated information Aggregated volume Price | 14 Ordinary Shares £17.2781 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

e) Date of the transaction 2016-10-11
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 a) Name Mr N Hirons
 b) Position/status SVP, Global Ethics & Compliance
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
 a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
 where transaction(s) has been conducted

Ordinary shares of 25 pence each
 ('Ordinary Shares')
 a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares
 under the Company's
 ShareReward Plan.

c) Price(s) and Volume(s)
 volume(s) £17.2781 8 (partnership shares)
 £17.2781 8 (matching shares)

d) Aggregated information 16 Ordinary Shares
 Aggregated volume Price £17.2781

e) Date of the transaction 2016-10-11
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 a) Name Mr S A Hussain
 b) Position/status President, Global Pharmaceuticals
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
 a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--------------------------------------------|------------------------------------------------------------------------------------------------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's ShareReward Plan. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £17.2781 7 (partnership shares) £17.2781 7 (matching shares) |
| d) Aggregated information | 14 Ordinary Shares |
| Aggregated volume Price | £17.2781 |
| e) Date of the transaction | 2016-10-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|---------------------------------------|------------------------|
| a) Name | Mr D S Redfern |
| b) Position/status | Chief Strategy Officer |
| c) Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--------------------------------------------|----------------------------------------------------------------------------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's ShareReward Plan. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £17.2781 8 (partnership shares) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£17.2781 8 (matching shares)

Aggregated information
d) 16 Ordinary Shares
Aggregated volume Price £17.2781
e) Date of the transaction 2016-10-11
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms C Thomas
b) Position/status SVP, Human Resources
c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan.

c) Price(s) and volume(s)
Price(s) Volume(s)
£17.2781 8 (partnership shares)
£17.2781 8 (matching shares)

Aggregated information
d) 16 Ordinary Shares
Aggregated volume Price £17.2781
e) Date of the transaction 2016-10-11
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P C Thomson
b) Position/status SVP, Communications & Government Affairs
c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan.
 - c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|------------------------|
| £17.2781 | 7 (partnership shares) |
| £17.2781 | 7 (matching shares) |
 - d) Aggregated information

| | |
|-------------------|--------------------|
| Aggregated volume | 14 Ordinary Shares |
| Price | £17.2781 |
 - e) Date of the transaction 2016-10-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Dr P J T Vallance
 - b) Position/status President, Pharmaceuticals R&D
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | |
|------------------------------------------------------|---------------------------------------------------------------------------------------|
| c) Price(s) and volume(s) | Price(s) Volume(s) £17.2781 7 (partnership shares) £17.2781 7 (matching shares) |
| d) Aggregated information Aggregated volume Price | 14 Ordinary Shares £17.2781 |
| e) Date of the transaction | 2016-10-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|---------------------------------------|----------------------|
| a) Name | Ms E Walmsley |
| b) Position/status | CEO Designate |
| c) Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--------------------------------------------|----------------------------------------------------------------------------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's ShareReward Plan. |

| | |
|---------------------------|---------------------------------------------------------------------------------------|
| c) Price(s) and volume(s) | Price(s) Volume(s) £17.2781 8 (partnership shares) £17.2781 8 (matching shares) |
|---------------------------|---------------------------------------------------------------------------------------|

| | |
|------------------------------------------------------|--------------------------------|
| d) Aggregated information Aggregated volume Price | 16 Ordinary Shares £17.2781 |
|------------------------------------------------------|--------------------------------|

| | |
|-----------------------------|------------------------------|
| e) Date of the transaction | 2016-10-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|---------|---------------|
| a) Name | Mrs V A Whyte |
|---------|---------------|

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| b) Position/status | Company Secretary |
| c) Initial notification/ amendment | Initial notification |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's ShareReward Plan. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £17.2781 7 (partnership shares) £17.2781 7 (matching shares) |
| d) Aggregated information | 14 Ordinary Shares |
| Aggregated volume Price | £17.2781 |
| e) Date of the transaction | 2016-10-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: October 12, 2016

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on
behalf of GlaxoSmithKline plc